New stock news | Lontium Semiconductor Corporation (688486.SH) submitted its listing application to the Hong Kong Stock Exchange.
According to the disclosure of the Hong Kong Stock Exchange on December 22, Longxin Semiconductor (Hefei) Co., Ltd. has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with CITIC Securities International as the exclusive sponsor.
According to the Hong Kong Stock Exchange disclosed on December 22, Longxun Semiconductor (Hefei) Co., Ltd. (referred to as Lontium Semiconductor Corporation (688486.SH)) submitted an application for listing on the main board of the Hong Kong Stock Exchange, with China Securities Co., Ltd. International as the exclusive sponsor. The prospectus shows that Lontium Semiconductor Corporation is a leading high-speed mixed-signal chip design company dedicated to building efficient and reliable "data highways" for smart terminals, devices, and AI applications. The company's products can achieve seamless data transmission and processing, and efficient interaction between computing, storage, and display units. Main applications include smart visual terminals, smart car applications, AR/VR devices, and AI with High-Performance Computing (HPC). According to Frost & Sullivan data, based on 2024 revenue calculations, in the video bridging chip market, the company ranks first in mainland China and among the top five Fabless design companies globally.
Related Articles
CK LIFE SCIENCES(00775): Positive results achieved in the mid-term analysis of the Phase IIb study of Halneuron in treating chemotherapy-induced neuropathic pain.
Bitcoin winter is coming? Whale Strategy (MSTR.US) pauses buying spree, hoarding $2.2 billion in cash to prepare for winter.
Shanghai Fosun Pharmaceutical (02196) responds to the acquisition of LvGu Pharmaceutical: The confirmatory clinical research on mannitol sodium capsules has been recognized by the Drug Evaluation Center, with a total of 580 cases enrolled.
CK LIFE SCIENCES(00775): Positive results achieved in the mid-term analysis of the Phase IIb study of Halneuron in treating chemotherapy-induced neuropathic pain.
Bitcoin winter is coming? Whale Strategy (MSTR.US) pauses buying spree, hoarding $2.2 billion in cash to prepare for winter.
Shanghai Fosun Pharmaceutical (02196) responds to the acquisition of LvGu Pharmaceutical: The confirmatory clinical research on mannitol sodium capsules has been recognized by the Drug Evaluation Center, with a total of 580 cases enrolled.
